gene_symbol
FCGR3A
hgnc_id
HGNC:3619
binding_type
receptor ligand recognition
cytotoxicity
NO
cytotoxicity_type
INDIRECT
cytotoxicity_mechanism
Naxitamab binds GD2 on tumor cells; its Fc engages CD16A on NK cells/macrophages to trigger ADCC/ADCP (and CDC) that kills GD2+ tumor cells, not the CD16A-expressing effector cells.
enzyme_product
Off
epitope
Off
variant
Off
isoform
Off
hla_specific
Off
gated
Off
other_modifier
Primary NK-cell Fc receptor mediating ADCC
trial_id_tar_ref
drug_id_tar_ref
disease_id_tar_ref
nct_id_tar_ref
NCT06574698
disease_id_num_tar_ref
546
drug_id_num_tar_ref
1505